Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 37.65 Thousand USD | -71.37% |
| 2022 | 131.52 Thousand USD | 51.2% |
| 2021 | 86.98 Thousand USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 1.17 Million USD | 25.1% |
| 2014 | 939.92 Thousand USD | -8.94% |
| 2013 | 1.03 Million USD | -22.49% |
| 2012 | 1.33 Million USD | -7.8% |
| 2011 | 1.44 Million USD | 10.35% |
| 2010 | 1.3 Million USD | 104.11% |
| 2009 | 641.28 Thousand USD | 174.59% |
| 2008 | 233.53 Thousand USD | 75.48% |
| 2007 | 133.08 Thousand USD | 101.11% |
| 2006 | 66.17 Thousand USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 196.21 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | 100.0% |
| 2023 Q3 | 7466.00 USD | -43.28% |
| 2023 Q1 | 17.02 Thousand USD | -87.06% |
| 2023 Q2 | 13.16 Thousand USD | -22.68% |
| 2023 Q4 | -37.65 Thousand USD | -604.33% |
| 2023 FY | 37.65 Thousand USD | -71.37% |
| 2022 FY | 131.52 Thousand USD | 51.2% |
| 2022 Q3 | 86.04 Thousand USD | 183.13% |
| 2022 Q4 | 131.52 Thousand USD | 52.85% |
| 2022 Q1 | 15.08 Thousand USD | -82.66% |
| 2022 Q2 | 30.39 Thousand USD | 101.49% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | 86.98 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | 86.98 Thousand USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | -262.25 Thousand USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q1 | 262.25 Thousand USD | 9.17% |
| 2015 Q3 | 329.79 Thousand USD | 36.26% |
| 2015 FY | 1.17 Million USD | 25.1% |
| 2015 Q4 | 240.23 Thousand USD | -27.16% |
| 2015 Q2 | 242.03 Thousand USD | -33.46% |
| 2015 Q1 | 363.77 Thousand USD | 64.97% |
| 2014 Q3 | 201.01 Thousand USD | -33.82% |
| 2014 FY | 939.92 Thousand USD | -8.94% |
| 2014 Q1 | 214.66 Thousand USD | -50.63% |
| 2014 Q2 | 303.75 Thousand USD | 41.5% |
| 2014 Q4 | 220.5 Thousand USD | 9.7% |
| 2013 FY | 1.03 Million USD | -22.49% |
| 2013 Q3 | 253.37 Thousand USD | 51.12% |
| 2013 Q1 | 176.4 Thousand USD | -59.03% |
| 2013 Q4 | 434.78 Thousand USD | 71.6% |
| 2013 Q2 | 167.66 Thousand USD | -4.95% |
| 2012 Q4 | 430.58 Thousand USD | 62.95% |
| 2012 Q1 | 380.52 Thousand USD | -4.05% |
| 2012 FY | 1.33 Million USD | -7.8% |
| 2012 Q2 | 256.4 Thousand USD | -32.62% |
| 2012 Q3 | 264.24 Thousand USD | 3.06% |
| 2011 Q1 | 349.93 Thousand USD | 17.37% |
| 2011 Q4 | 396.59 Thousand USD | 13.2% |
| 2011 Q2 | 347.56 Thousand USD | -0.68% |
| 2011 FY | 1.44 Million USD | 10.35% |
| 2011 Q3 | 350.35 Thousand USD | 0.8% |
| 2010 Q2 | 304.69 Thousand USD | -10.77% |
| 2010 FY | 1.3 Million USD | 104.11% |
| 2010 Q4 | 298.15 Thousand USD | -18.22% |
| 2010 Q1 | 341.48 Thousand USD | 23.98% |
| 2010 Q3 | 364.57 Thousand USD | 19.65% |
| 2009 Q4 | 275.44 Thousand USD | 37.95% |
| 2009 FY | 641.28 Thousand USD | 174.59% |
| 2009 Q1 | 124.27 Thousand USD | 1355.35% |
| 2009 Q2 | 41.89 Thousand USD | -66.29% |
| 2009 Q3 | 199.67 Thousand USD | 376.61% |
| 2008 Q3 | 100 Thousand USD | 0.0% |
| 2008 Q1 | 125 Thousand USD | 367.41% |
| 2008 FY | 233.53 Thousand USD | 75.48% |
| 2008 Q4 | 8539.00 USD | -91.46% |
| 2008 Q2 | - USD | -100.0% |
| 2007 Q2 | 26.67 Thousand USD | -19.39% |
| 2007 Q1 | 33.08 Thousand USD | 0.0% |
| 2007 Q4 | 26.74 Thousand USD | -42.59% |
| 2007 Q3 | 46.58 Thousand USD | 74.65% |
| 2007 FY | 133.08 Thousand USD | 101.11% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q3 | 66.17 Thousand USD | 0.0% |
| 2006 FY | 66.17 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | -100.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q2 | 44.23 Thousand USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | 118.64 Thousand USD | 168.21% |
| 2004 Q4 | 33.33 Thousand USD | -71.9% |
| 2004 FY | 196.21 Thousand USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | 81.36% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 4.52 Million USD | 99.169% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | 53.515% |
| Azitra, Inc. | 686 Thousand USD | 94.511% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 94.932% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| iBio, Inc. | 225 Thousand USD | 83.265% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 99.579% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | 96.565% |
| Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | 42.648% |
| NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 99.744% |
| NanoViricides, Inc. | - USD | -Infinity% |
| BiomX Inc. | -357 Thousand USD | 110.547% |
| BiomX Inc. | -357 Thousand USD | 110.547% |
| Protalix BioTherapeutics, Inc. | 65.49 Million USD | 99.943% |
| Palatin Technologies, Inc. | 4.49 Million USD | 99.161% |
| Scorpius Holdings, Inc. | 6.99 Million USD | 99.462% |